+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Soft Tissue Anchors - Global Strategic Business Report

  • PDF Icon

    Report

  • 466 Pages
  • November 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6106038
The global market for Soft Tissue Anchors was valued at US$730.4 Million in 2025 and is projected to reach US$1.1 Billion by 2032, growing at a CAGR of 5.3% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Soft Tissue Anchors Market - Key Trends & Drivers Summarized

Innovating Orthopedic Repair: The Rise of Precision-Engineered Anchors in Soft Tissue Fixation

Why Are Soft Tissue Anchors Becoming Indispensable in Modern Surgical Repair?

Soft tissue anchors, also referred to as suture anchors or fixation devices, play a critical role in orthopedic and sports medicine surgeries by ensuring stable reattachment of ligaments, tendons, and other soft tissues to bone structures. As surgical approaches become increasingly minimally invasive and patient-specific, these devices have evolved from simple metal anchors to sophisticated bioabsorbable and all-suture constructs with improved biomechanical performance. The growing incidence of rotator cuff injuries, ACL reconstructions, shoulder dislocations, and hip labral tears has contributed to the rising deployment of soft tissue anchors across arthroscopic procedures. Their utility in complex joint reconstructions has elevated their importance in both trauma and degenerative orthopedic interventions.

Modern soft tissue anchors are now designed with advanced thread geometries, materials such as polyether ether ketone (PEEK), and integrated suture eyelets to offer optimized pull-out strength, better cortical engagement, and minimal bone disruption. Biocomposite and bioabsorbable variants promote natural tissue healing by gradually resorbing within the body, eliminating the need for secondary removal surgeries. These innovations have enhanced patient recovery profiles, enabled faster rehabilitation, and reduced post-operative complications-key drivers propelling their adoption in both inpatient and ambulatory surgical settings.

Which Specialties and Surgical Advancements Are Propelling Market Uptake?

The soft tissue anchors market is gaining momentum across orthopedics, sports medicine, trauma surgery, and veterinary applications. Within orthopedic surgery, shoulder repair-particularly rotator cuff and labral repairs-remains the largest application segment. The increasing incidence of shoulder dislocations, especially among athletes and aging populations, is contributing to a consistent rise in arthroscopic anchor procedures. Knee repairs involving meniscal root fixation and multiligament reconstructions also constitute a significant share of the market. Additionally, hip and ankle arthroscopies are adopting novel anchor systems designed for limited anatomical access and high-tensile load bearing.

The emergence of knotless anchor systems and double-row fixation techniques has transformed surgical workflows, especially in high-throughput centers. Knotless designs reduce surgical complexity, enhance reproducibility, and lower the risk of suture entanglement or irritation. Moreover, robotic-assisted arthroscopy and 3D pre-surgical planning platforms are increasing the precision of anchor placement, further improving long-term clinical outcomes. These trends are encouraging hospitals and ambulatory surgical centers to adopt advanced fixation systems tailored to patient anatomy, injury grade, and procedural workflow.

Veterinary medicine has also embraced soft tissue anchors, particularly in large animal orthopedics and companion animal surgery. Ligament and tendon injuries in dogs and horses are now routinely treated with the same minimally invasive techniques used in human surgery, expanding the market across veterinary orthopedics. As demand for motion-preserving, biologically favorable repairs continues to grow, the use of hybrid anchors-combining metal cores with bioactive coatings-has emerged as an area of strong innovation.

What Regional and Institutional Trends Are Shaping Soft Tissue Anchor Adoption?

Regionally, North America remains the most mature and innovation-intensive market for soft tissue anchors, driven by high surgical volumes, reimbursement frameworks, and the presence of leading device manufacturers. The U.S. market benefits from robust investments in arthroscopic surgery training, clinical research, and product innovation. Institutions such as the American Academy of Orthopaedic Surgeons (AAOS) and International Society of Arthroscopy are continuously expanding best-practice frameworks that favor advanced fixation systems in both elective and trauma-related surgeries.

Europe is steadily growing in adoption, with countries like Germany, the UK, France, and Italy prioritizing minimally invasive orthopedic interventions. Public-private collaborations in surgical innovation, coupled with a strong emphasis on evidence-based outcomes, have supported market growth. Regulatory clarity under MDR (Medical Device Regulation) has also encouraged early adoption of bioabsorbable anchors with CE-certified labeling. Asia Pacific is emerging as a high-potential region due to the rising geriatric population, growing interest in sports participation, and increasing accessibility to arthroscopic care. India, Japan, South Korea, and China are investing heavily in surgical training centers and orthopedic infrastructure, making them growth hotspots.

Latin America and the Middle East are gradually adopting soft tissue anchors through hospital network expansions and international partnerships. While limited insurance coverage may hinder growth in some emerging regions, donations, training collaborations, and mobile surgical units are bridging the accessibility gap. The increased demand for ambulatory surgical care and orthopedic day surgeries in urban centers is further promoting market penetration in these regions.

What Is Accelerating Market Expansion and Where Are New Opportunities Emerging?

The growth in the soft tissue anchors market is driven by several factors including the increased prevalence of musculoskeletal injuries, demand for minimally invasive procedures, and rising investment in sports and trauma care infrastructure. One of the strongest market accelerators is the shift toward outpatient arthroscopic surgeries, which require efficient, reliable, and low-profile fixation systems. Advances in anchor materials, including bioactive ceramics and radiolucent polymers, are reducing implant-related complications while promoting bone in-growth and natural healing responses.

Furthermore, the integration of smart surgical tools, augmented reality in pre-surgical planning, and patient-specific instrumentation are enhancing the accuracy and reproducibility of anchor placement. Startups and major medical device firms alike are investing in anchor systems with load-sensing capabilities and antimicrobial coatings, aimed at reducing post-op infections and improving biomechanical feedback. These technological developments are expected to create differentiation and fuel premium product segments.

New opportunities are also emerging in emerging markets where orthopedic care is scaling through public health investments. Expanding geriatric populations, increased participation in sports, and greater awareness of orthopedic rehabilitation are creating robust long-term demand. Additionally, the growing use of anchors in ligament repairs beyond shoulder and knee joints-such as elbow, wrist, and foot surgeries-is broadening application scope. As surgeons demand more adaptable, biocompatible, and patient-tailored anchor systems, the global soft tissue anchors market is poised for sustained, innovation-driven growth across both established and emerging healthcare economies.

Report Scope

The report analyzes the Soft Tissue Anchors market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Product (Absorbable Soft Tissue Anchors, Non Absorbable Soft Tissue Anchors); Material (Metallic Suture Anchor, Bio-absorbable Suture Anchor, PEEK Suture, All Suture, Bio-composite Suture Anchor); Tying Type (Knotted Suture Anchors, Knotless Suture Anchors); End-Use (Hospitals End-Use, Emergency Medical Services End-Use, Clinics End-Use, Ambulatory Surgery Centers End-Use)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Absorbable Soft Tissue Anchors segment, which is expected to reach US$715.7 Million by 2032 with a CAGR of a 6.2%. The Non Absorbable Soft Tissue Anchors segment is also set to grow at 3.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $199.0 Million in 2025, and China, forecasted to grow at an impressive 9.3% CAGR to reach $228.9 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Soft Tissue Anchors Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Soft Tissue Anchors Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Soft Tissue Anchors Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Acumed, Anika Therapeutics, Aroa Biosurgery, Arthrex, Biomet (now part of Zimmer) and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Soft Tissue Anchors market report include:

  • Acumed
  • Anika Therapeutics
  • Aroa Biosurgery
  • Arthrex
  • Biomet (now part of Zimmer)
  • CONMED Corporation
  • DePuy Mitek (J&J)
  • DePuy Synthes (Johnson & Johnson)
  • ENOVIS (formerly DJO / Wright Medical)
  • Leda Orthopaedics (Groupe?Lépine)
  • MedShape (Enovis)
  • NeoSys Medical Solutions
  • OSSIO
  • Smith & Nephew
  • Stryker
  • Tulpar Medical
  • Zimmer Biomet

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • World Market Trajectories
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Soft Tissue Sarcoma - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Rare Cancer Types Drives Investment in Soft Tissue Sarcoma Treatments
  • Growth in Personalized Oncology Enhances Molecular Targeting Approaches
  • Increased Use of Radiotherapy and Chemotherapy Combinations Boosts Treatment Uptake
  • Expansion of Immunotherapy Clinical Trials Spurs Therapeutic Advancements
  • FDA and EMA Orphan Drug Designations Accelerate Market Entry
  • Development of Biomarkers for Sarcoma Subtypes Supports Diagnostic Precision
  • Growing Adoption of Next-Generation Sequencing Enables Genetic Profiling
  • Collaborative Research Efforts Fuel Drug Discovery and Repurposing Initiatives
  • Patient Advocacy Group Involvement Improves Clinical Trial Enrollment
  • Integration of Digital Pathology Tools Enhances Diagnostic Accuracy
  • Rise in Multidisciplinary Cancer Care Centers Broadens Access to Sarcoma Therapies
  • Public-Private Partnerships Facilitate R&D in Rare Cancer Segments
  • Expansion of Soft Tissue Sarcoma Registries Strengthens Data-Driven Insights
  • Surge in Targeted Therapy Approval Rates Encourages Pharmaceutical Investment
  • Use of Robotic-Assisted Surgery Enhances Tumor Resection Outcomes
  • Increasing Insurance Coverage for Rare Cancers Expands Patient Accessibility
  • High Demand for Post-Treatment Monitoring Fuels Companion Diagnostic Development
  • Scientific Advances in Tumor Microenvironment Research Propel Innovation
  • Focus on Limb-Sparing Procedures Increases Need for Adjuvant Therapies
  • International Collaboration on Treatment Guidelines Promotes Standardized Care Pathways
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Soft Tissue Sarcoma Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Targeted Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Targeted Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Targeted Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Anti-Angiogenesis Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Anti-Angiogenesis Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Anti-Angiogenesis Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Specialty Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
AUSTRALIA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acumed
  • Anika Therapeutics
  • Aroa Biosurgery
  • Arthrex
  • Biomet (now part of Zimmer)
  • CONMED Corporation
  • DePuy Mitek (J&J)
  • DePuy Synthes (Johnson & Johnson)
  • ENOVIS (formerly DJO / Wright Medical)
  • Leda Orthopaedics (Groupe?Lépine)
  • MedShape (Enovis)
  • NeoSys Medical Solutions
  • OSSIO
  • Smith & Nephew
  • Stryker
  • Tulpar Medical
  • Zimmer Biomet

Table Information